当前位置: X-MOL首页全球导师 国内导师 › 马英

个人简介

教育背景 2005.10-2009.06 天津理工大学药学专业获学士学位 2010.09-2015.07 天津医科大学药理学专业获博士学位 工作经历 2015.07- 讲师,药学院,天津医科大学

研究领域

新型抗肿瘤药物研究

近期论文

查看导师最新文章 (温馨提示:请注意重名现象,建议点开原文通过作者单位确认)

1.Sun Y-Z, Chen X-B, Wang R-R, Li W-Y, Ma Y*. Exploring the effect of N308D mutation on protein tyrosine phosphatase-2 cause gain-of-function activity by a molecular dynamics study [J]. Journal of Cellular Biochemistry. 2019;120(4):5949-61. 2.Wei-Ya L, Yu-Qing D, Yang-Chun M, Xin-Hua L, Ying M*, Wang R-L*. Exploring the cause of the inhibitor 4AX attaching to binding site disrupting protein tyrosine phosphatase 4A1 trimerization by molecular dynamic simulation [J]. Journal of Biomolecular Structure and Dynamics. 2019:1-12. 3.Wang R-R, Ma Y#, Du S, Li W-Y, Sun Y-Z, Zhou H, et al. Exploring the reason for increased activity of SHP2 caused by D61Y mutation through molecular dynamics [J]. Comput Biol Chem. 2019;78:133-43. 4.Ma Y, Li H-L, Chen X-B, Jin W-Y, Zhou H, Ma Y*, et al. 3D QSAR Pharmacophore Based Virtual Screening for Identification of Potential Inhibitors for CDC25B [J]. Comput Biol Chem. 2018;73:1-12. 5.Jin W-Y, Ma Y#,*, Li W-Y, Li H-L, Wang R-L*. Scaffold-based novel SHP2 allosteric inhibitors design using Receptor-Ligand pharmacophore model, virtual screening and molecular dynamics [J]. Comput Biol Chem. 2018;73:179-88. 6.Li W-Y, Wei H-Y, Sun Y-Z, Zhou H, Ma Y*, Wang R-L*. Exploring the effect of E76K mutation on SHP2 cause gain-of-function activity by a molecular dynamics study[J]. Journal of Cellular Biochemistry. 2018;119(12):9941-56. 7.Zhu Y#, Han Y#, Ma Y#, Yang P. ADME/toxicity prediction and antitumor activity of novel nitrogenous heterocyclic compounds designed by computer targeting of alkylglycerone phosphate synthase[J]. Oncol Lett. 2018. 8.Liu X, Jing Z, Jia W-Q, Wang S-Q, Ma Y*, Xu W-R, et al. Identification of novel PPARα/γ dual agonists by virtual screening, ADMET prediction and molecular dynamics simulations[J]. Journal of Biomolecular Structure and Dynamics. 2017;36(11):2988-3002. 9.Li H-L, Ma Y#,*, Zheng C-J, Jin W-Y, Liu W-S, Wang R-L*. Exploring the effect of D61G mutation on SHP2 cause gain of function activity by a molecular dynamics study [J]. Journal of Biomolecular Structure and Dynamics. 2017;36(14):3856-68. 10.Ying Ma#, Hui-Yu Wei#, Yu-Ze Zhang, Wen-Yan Jin, Hong-Lian Li, Hui Zhou, Xian-Chao Cheng, and Run-Ling Wang*. Synthesis, bioactivity, 3D-QSAR studies of novel dibenzofuran derivatives as PTP-MEG2 inhibitors [J]. Oncotarget, 2017, 8(24); 38466-38481. 11. Hong-Lian Li#, Ying Ma#, Ying Ma,Yu Li, Xiu-Bo Chen, Wei-Li Dong, and Run-Ling Wang*.The design of novel inhibitors for treating cancer by targeting CDC25B through disruption of CDC25B-CDK2/Cyclin A interaction using computational approaches [J]. Oncotarget, 2017, 8 (20); 33225-33240. 12.Ying Ma#, Yuan-Yuan Jin#, Ye-Liu Wang, Run-Ling Wang*, Xin-Hua Lu, De-Xin Kong, Wei-Ren Xu. The Discovery of a Novel and Selective Inhibitor of PTP1B Over TCPTP: 3D QSAR Pharmacophore Modeling, Virtual Screening, Synthesis, and Biological Evaluation [J]. Chem Biol Drug Des, 2014, 83; 697-709. 13.Yu-Qing Duan#, Ying Ma#, Xue-Jiao Wang, Yuan-Yuan Jin, Run-Ling Wang*, Wei-Li Dong, Wei-Ren Xu, De-Xin Kong, Shu-Qing Wang.Design potential selective inhibitors for treating cancer by targeting the Src Homology 2 (SH2) Domain-Containing Phosphatase 2 (Shp2) with core hopping approach [J]. Protein & Peptide Letters, 2014, 21; 556-563. 14.Yuan-Yuan Jin#, Ying Ma#, Quan-Xiong Gao, Run-Ling Wang*, Shu-Qing Wang, Wei-Ren Xu. Design of specific inhibitors of the protein tyrosine phosphatase SHP-2 by virtual screening and core hopping method [J]. Molecular Simulation, 2014, 40 (12); 904-911. 15.Ying Ma#, Su-Xia Sun#, Xian-Chao Cheng, Shu-Qing Wang,Wei-Li Dong,Run-Ling Wang*,Wei-Ren Xu. Design and Synthesis of Imidazolidine-2,4-Dione Derivatives as Selective Inhibitors by Targeting Protein Tyrosine Phosphatase-1B Over T-Cell Protein Tyrosine Phosphatase [J]. Chem Biol Drug Des, 2013, 82; 595-602. 16.Ying Ma#, Shu-Qing Wang#,*, Wei-Ren Xu, Run-Ling Wang*, Kuo-Chen Chou Design Novel Dual Agonists for Treating Type-2 Diabetes by Targeting Peroxisome Proliferator-Activated Receptors with Core Hopping Approach [J].PLoS ONE, 2012, 7( 6): e38546.

推荐链接
down
wechat
bug